Commonwealth Equity Services’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.5M Buy
12,116
+525
+5% +$157K 0.01% 1483
2026
Q1
$2.99M Buy
11,591
+1,704
+17% +$453K ﹤0.01% 1699
2025
Q4
$2.44M Sell
9,887
-119
-1% -$25K ﹤0.01% 1828
2025
Q3
$1.77M Buy
10,006
+1,791
+22% +$268K ﹤0.01% 2100
2025
Q2
$1.13M Buy
8,215
+912
+12% +$134K ﹤0.01% 2462
2025
Q1
$1.32M Buy
7,303
+2,437
+50% +$410K ﹤0.01% 2247
2024
Q4
$762K Buy
4,866
+190
+4% +$33.7K ﹤0.01% 2615
2024
Q3
$851K Buy
4,676
+52
+1% +$10K ﹤0.01% 2478
2024
Q2
$849K Buy
4,624
+41
+0.9% +$6.88K ﹤0.01% 2404
2024
Q1
$815K Sell
4,583
-1
-0% -$139 ﹤0.01% 2400
2023
Q4
$569K Buy
4,584
+158
+4% +$17.5K ﹤0.01% 2589
2023
Q3
$513K Buy
4,426
+110
+3% +$13.4K ﹤0.01% 2564
2023
Q2
$507K Hold
4,316
﹤0.01% 2614
2023
Q1
$345 Hold
4,316
﹤0.01% 2840
2022
Q4
$341K Sell
4,316
-5
-0.1% -$371 ﹤0.01% 2772
2022
Q3
$301K Buy
4,321
+31
+0.7% +$2.24K ﹤0.01% 2826
2022
Q2
$281K Buy
4,290
+772
+22% +$48K ﹤0.01% 2889
2022
Q1
$234K Buy
+3,518
New +$220K ﹤0.01% 3183

Other funds holding KRYS

Commonwealth Equity Services's KRYS Position: Q2 2026 in Review

Commonwealth Equity Services increased its Krystal Biotech (KRYS) stake by 4.5% in Q2 2026, buying an estimated $157K and bringing the position to 12,116 shares worth $4.5M. The position accounts for 0.01% of the portfolio, ranked #1483.

Commonwealth Equity Services first reported a position in KRYS in Q1 2022 and has held it in 18 quarters since. 104 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Commonwealth Equity Services held 12,116 shares of Krystal Biotech worth $4.5M as of Q2 2026.
  • Commonwealth Equity Services bought 525 Krystal Biotech shares in Q2 2026, an estimated $157K.
  • Krystal Biotech made up 0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #1483 holding.
  • Commonwealth Equity Services first reported a position in Krystal Biotech in Q1 2022 and has held it in 18 quarters since.
  • 104 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.